Loading...

Lupin

BSE:500257
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
500257
BSE
₹327B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
500257 Share Price and Events
7 Day Returns
-1%
BSE:500257
-0.7%
IN Pharmaceuticals
-1.3%
IN Market
1 Year Returns
-20.7%
BSE:500257
-14.9%
IN Pharmaceuticals
-1.6%
IN Market
500257 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lupin (500257) -1% -4.1% -4.3% -20.7% -50.7% -27.7%
IN Pharmaceuticals -0.7% -3.9% -11.1% -14.9% -17.1% 15%
IN Market -1.3% 4.7% 0.7% -1.6% 32.8% 41.8%
1 Year Return vs Industry and Market
  • 500257 underperformed the Pharmaceuticals industry which returned -14.9% over the past year.
  • 500257 underperformed the Market in India which returned -1.6% over the past year.
Price Volatility
500257
Industry
5yr Volatility vs Market

Value

 Is Lupin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Lupin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Lupin.

BSE:500257 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 29 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.7%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BSE:500257
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 35%) (25.15%))
0.829
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.829 * 8.6%)
14.68%

Discounted Cash Flow Calculation for BSE:500257 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Lupin is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BSE:500257 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 14.68%)
2019 12,157.25 Analyst x8 10,601.41
2020 10,911.21 Analyst x14 8,297.17
2021 15,038.69 Analyst x16 9,972.29
2022 24,103.50 Analyst x2 13,937.78
2023 28,982.99 Est @ 20.24% 14,614.53
2024 33,746.55 Est @ 16.44% 14,838.82
2025 38,393.45 Est @ 13.77% 14,721.62
2026 42,963.81 Est @ 11.9% 14,365.79
2027 47,517.03 Est @ 10.6% 13,854.93
2028 52,118.32 Est @ 9.68% 13,251.77
Present value of next 10 years cash flows ₹128,456.09
BSE:500257 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹52,118.32 × (1 + 7.55%) ÷ (14.68% – 7.55%)
₹786,627.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹786,627.38 ÷ (1 + 14.68%)10
₹200,010.34
BSE:500257 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹128,456.09 + ₹200,010.34
₹328,466.43
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹328,466.43 / 452.58
₹725.76
BSE:500257 Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹725.76
Current discount Discount to share price of ₹722.25
= -1 x (₹722.25 - ₹725.76) / ₹725.76
0.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Lupin is available for.
Intrinsic value
0%
Share price is ₹722.25 vs Future cash flow value of ₹725.76
Current Discount Checks
For Lupin to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Lupin's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Lupin's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lupin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lupin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:500257 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹13.41
BSE:500257 Share Price ** BSE (2019-06-14) in INR ₹722.25
India Pharmaceuticals Industry PE Ratio Median Figure of 115 Publicly-Listed Pharmaceuticals Companies 18.1x
India Market PE Ratio Median Figure of 2,824 Publicly-Listed Companies 15.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lupin.

BSE:500257 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:500257 Share Price ÷ EPS (both in INR)

= 722.25 ÷ 13.41

53.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lupin is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
  • Lupin is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Lupin's expected growth come at a high price?
Raw Data
BSE:500257 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 53.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 29 Analysts
39.3%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 1.37x
India Market PEG Ratio Median Figure of 521 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

BSE:500257 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 53.86x ÷ 39.3%

1.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lupin is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Lupin's assets?
Raw Data
BSE:500257 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹303.74
BSE:500257 Share Price * BSE (2019-06-14) in INR ₹722.25
India Pharmaceuticals Industry PB Ratio Median Figure of 134 Publicly-Listed Pharmaceuticals Companies 1.66x
India Market PB Ratio Median Figure of 3,653 Publicly-Listed Companies 1x
BSE:500257 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:500257 Share Price ÷ Book Value per Share (both in INR)

= 722.25 ÷ 303.74

2.38x

* Primary Listing of Lupin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lupin is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Lupin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Lupin has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Lupin expected to perform in the next 1 to 3 years based on estimates from 29 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lupin expected to grow at an attractive rate?
  • Lupin's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Lupin's earnings growth is expected to exceed the India market average.
  • Lupin's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
BSE:500257 Future Growth Rates Data Sources
Data Point Source Value (per year)
BSE:500257 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 29 Analysts 39.3%
BSE:500257 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 29 Analysts 10.4%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.3%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 11.6%
India Market Earnings Growth Rate Market Cap Weighted Average 16.6%
India Market Revenue Growth Rate Market Cap Weighted Average 9.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:500257 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 29 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:500257 Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-03-31 238,276 34,522 25,110 4
2021-03-31 204,716 25,261 18,493 26
2020-03-31 183,784 22,146 13,336 26
BSE:500257 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 167,182 6,066
2018-12-31 163,114 -4,666
2018-09-30 157,822 -931
2018-06-30 157,829 960
2018-03-31 157,966 17,512 2,513
2017-12-31 159,233 14,150
2017-09-30 164,306 18,264
2017-06-30 167,693 20,336
2017-03-31 173,674 41,135 25,575
2016-12-31 173,910 29,351
2016-09-30 164,558 28,265
2016-06-30 154,918 25,841

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lupin's earnings are expected to grow significantly at over 20% yearly.
  • Lupin's revenue is expected to grow by 10.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:500257 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 29 Analyst Estimates (S&P Global) See Below

All data from Lupin Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500257 Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-03-31 53.41 72.10 44.73 5.00
2021-03-31 40.87 49.10 31.80 27.00
2020-03-31 29.33 34.70 23.10 24.00
BSE:500257 Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 13.41
2018-12-31 -10.32
2018-09-30 -2.06
2018-06-30 2.12
2018-03-31 5.56
2017-12-31 31.33
2017-09-30 40.45
2017-06-30 45.06
2017-03-31 56.69
2016-12-31 65.07
2016-09-30 62.70
2016-06-30 57.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Lupin is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Lupin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lupin has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Lupin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lupin's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lupin's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Lupin's 1-year earnings growth exceeds its 5-year average (141.4% vs -25.6%)
  • Lupin's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (141.4% vs 24.6%).
Earnings and Revenue History
Lupin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lupin Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500257 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 167,181.80 6,065.50 31,512.90
2018-12-31 163,114.30 -4,665.50 32,875.10
2018-09-30 157,821.80 -930.70 31,720.70
2018-06-30 157,829.00 959.60 31,032.60
2018-03-31 157,965.50 2,512.60 30,718.20
2017-12-31 159,233.30 14,150.10 30,361.30
2017-09-30 164,305.80 18,263.90 30,717.00
2017-06-30 167,693.10 20,335.70 30,566.90
2017-03-31 173,673.80 25,574.60 30,418.70
2016-12-31 173,910.30 29,350.80 28,249.30
2016-09-30 164,558.20 28,265.30 26,371.90
2016-06-30 154,918.20 25,840.90 24,576.00
2016-03-31 141,316.10 22,607.40 22,930.70
2015-12-31 131,054.60 20,106.20 36,591.90 1,682.00
2015-09-30 127,272.80 20,823.20 35,467.00 1,682.00
2015-06-30 125,794.20 23,035.20 34,614.20 1,682.00
2015-03-31 127,700.10 24,032.40 18,569.90
2014-12-31 128,123.90 24,092.30 32,708.60 1,311.00
2014-09-30 126,567.40 22,839.10 32,337.00 1,311.00
2014-06-30 121,512.10 20,600.50 31,630.10 1,311.00
2014-03-31 112,865.70 18,363.70 30,807.90 1,311.00
2013-12-31 107,518.60 16,914.50 28,011.00 890.20
2013-09-30 102,309.30 15,505.50 27,421.70 890.20
2013-06-30 98,637.40 14,348.30 26,771.90 890.20
2013-03-31 96,413.00 13,141.60 26,706.40 890.20
2012-12-31 89,793.30 10,617.20 23,080.70 771.60
2012-09-30 82,985.40 9,615.50 22,439.50 771.60
2012-06-30 77,691.20 9,379.60 21,708.90 771.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Lupin has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Lupin used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Lupin's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Lupin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lupin has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Lupin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lupin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lupin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lupin's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lupin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lupin Company Filings, last reported 2 months ago.

BSE:500257 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 137,890.90 82,219.30 37,364.00
2018-12-31 135,505.70 85,045.80 31,082.50
2018-09-30 135,505.70 85,045.80 31,082.50
2018-06-30 136,171.40 71,428.00 17,015.20
2018-03-31 136,171.40 71,428.00 17,015.20
2017-12-31 139,884.60 76,963.10 24,178.70
2017-09-30 139,884.60 76,963.10 24,178.70
2017-06-30 135,320.90 79,660.90 28,083.40
2017-03-31 135,320.90 79,660.90 28,083.40
2016-12-31 125,242.00 68,422.10 19,238.00
2016-09-30 125,242.00 68,422.10 19,238.00
2016-06-30 110,164.50 71,775.20 8,399.30
2016-03-31 111,954.50 71,775.20 8,054.50
2015-12-31 99,015.60 18,654.70 18,555.50
2015-09-30 99,015.60 18,654.70 18,555.50
2015-06-30 88,981.60 5,371.20 21,372.40
2015-03-31 88,981.60 5,371.20 21,372.40
2014-12-31 82,273.70 5,003.50 13,934.00
2014-09-30 82,273.70 5,003.50 13,934.00
2014-06-30 69,985.10 6,537.40 9,739.10
2014-03-31 69,985.10 6,537.40 9,739.10
2013-12-31 61,973.70 9,216.20 6,427.10
2013-09-30 61,973.70 9,216.20 6,427.10
2013-06-30 52,636.30 11,644.90 4,348.80
2013-03-31 52,636.30 11,644.90 4,348.80
2012-12-31 47,295.00 14,160.20 5,130.60
2012-09-30 47,295.00 14,160.20 5,130.60
2012-06-30 40,851.80 16,400.20 4,024.70
  • Lupin's level of debt (59.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (9.3% vs 59.6% today).
  • Debt is well covered by operating cash flow (21.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5.8x coverage).
X
Financial health checks
We assess Lupin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lupin has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Lupin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.69%
Current annual income from Lupin dividends. Estimated to be 0.96% next year.
If you bought ₹2,000 of Lupin shares you are expected to receive ₹14 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Lupin's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.53%).
  • Lupin's dividend is below the markets top 25% of dividend payers in India (2.04%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:500257 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 29 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 74 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1450 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:500257 Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2022-03-31 7.30 6.00
2021-03-31 7.50 26.00
2020-03-31 6.30 24.00
BSE:500257 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-15 5.000 0.672
2018-07-16 5.000 0.596
2017-07-07 7.500 0.850
2017-05-24 7.500 0.670
2016-07-11 7.500 0.507
2015-07-27 7.500 0.439
2014-08-01 6.000 0.386
2014-02-03 6.000 0.613
2013-07-12 4.000 0.459
2013-05-08 4.000 0.513
2012-07-30 3.200 0.534
2011-05-12 3.000 0.625
2010-05-05 2.700 0.664

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lupin has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Dividend payments have increased, but Lupin only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Lupin's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.7x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be thoroughly covered by earnings (7.5x coverage).
X
Income/ dividend checks
We assess Lupin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lupin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lupin has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Lupin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vinita Gupta
COMPENSATION ₹172,200,000
AGE 50
TENURE AS CEO 5.8 years
CEO Bio

Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive Officer of Lupin Pharmacuticls Inc., the U.S. wholly owned subsidiary of Lupin since 2003 and also has been its Managing Director since October 11, 2003. She is an employee of Lupin Gmbh, Switzerland, wholly-owned subsidiary of Lupin Limited. She served as the President at Lupin Pharmaceuticals, Inc. until August 2010. She has been a Director of Intrexon Corporation since April 25, 2017. She has served as a Director of Lupin since 2001 and Lupin's Japanese subsidiary Kyowa Pharmaceuticals since 2007. She served as a Non-Executive Director at Lupin Limited. She served as a Whole-Time Director at Lupin Ltd until October 10, 2003. She won Entrepreneur of the Year as part of the 2016 Forbes India Leadership Awards and was named 2015 Ernst & Young Entrepreneur of the Year. She received Hall of Fame Award for The Most Powerful Business Women, 2017 by Business Today. She is regularly named in Forbes Asia Top 50 Power Business women listings for Asia Pacific. She is a Pharmacy Graduate from the University of Mumbai. She holds an MBA from the J. L. Kellogg Graduate School of Management, USA.

CEO Compensation
  • Vinita's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Vinita's remuneration is higher than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Lupin management team in years:

5.8
Average Tenure
50
Average Age
  • The average tenure for the Lupin management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Vinita Gupta

TITLE
CEO & Executive Director
COMPENSATION
₹172M
AGE
50
TENURE
5.8 yrs

Kamal Sharma

TITLE
Vice Chairman & Advisor
COMPENSATION
₹187M
AGE
69

Nilesh Gupta

TITLE
MD & Executive Director
COMPENSATION
₹91M
TENURE
5.8 yrs

Rajvardhan Satam

TITLE
Company Secretary
COMPENSATION
₹8M
TENURE
11.1 yrs

Lalit Singal

TITLE
Head of Finance & Accounts
AGE
50

Alok Ghosh

TITLE
President of Technical Operations
COMPENSATION
₹46M

Mayur Danait

TITLE
Chief Information Officer
COMPENSATION
₹16M
AGE
44

Arvind Bothra

TITLE
Head of Investor Relations

Sofia Mumtaz

TITLE
Head of Pipeline Management & Legal

Pooja Thakran

TITLE
VP of Corporate Communications
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Lupin board of directors in years:

6.7
Average Tenure
69.5
Average Age
  • The tenure for the Lupin board of directors is about average.
Board of Directors

Manju Gupta

TITLE
Chairman
COMPENSATION
₹17M
AGE
74
TENURE
1.8 yrs

Vinita Gupta

TITLE
CEO & Executive Director
COMPENSATION
₹172M
AGE
50

Kamal Sharma

TITLE
Vice Chairman & Advisor
COMPENSATION
₹187M
AGE
69
TENURE
5.8 yrs

Nilesh Gupta

TITLE
MD & Executive Director
COMPENSATION
₹91M
TENURE
10.7 yrs

Kamalaksha Mada

TITLE
Independent Non-Executive Director
COMPENSATION
₹3M
AGE
85

Rajendra Shah

TITLE
Independent Director
COMPENSATION
₹4M
AGE
87
TENURE
13.7 yrs

Richard Zahn

TITLE
Independent Non-Executive Director
COMPENSATION
₹7M
AGE
66
TENURE
9.4 yrs

Dileep Choksi

TITLE
Independent Director
COMPENSATION
₹3M
AGE
69
TENURE
6.7 yrs

Jean-Luc Bélingard

TITLE
Independent Director & Member of Strategic Advisory Board
COMPENSATION
₹7M
AGE
70
TENURE
3.7 yrs

Franceso Granata

TITLE
Member of Strategic Advisory Board
Who owns this company?
Recent Insider Trading
  • Lupin insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
28. May 19 Sell Alok Ghosh Individual 24. May 19 24. May 19 -5,000 ₹761.00 ₹-3,805,000
24. May 19 Sell Gautam Pareek Individual 20. May 19 21. May 19 -3,200 ₹773.00 ₹-2,453,451
19. Feb 19 Sell Milind Sindkhedkar Individual 14. Feb 19 14. Feb 19 -2,000 ₹801.85 ₹-1,603,693
15. Feb 19 Sell Deepak Didwania Individual 17. Jan 19 29. Jan 19 -1,487 ₹865.13 ₹-1,286,455
07. Dec 18 Sell T. Vijaya Kumar Individual 05. Nov 18 05. Dec 18 -2,500 ₹873.68 ₹-2,184,211
16. Nov 18 Sell M. Ramesh Individual 15. Oct 18 15. Oct 18 -2,000 ₹875.00 ₹-1,750,000
27. Sep 18 Sell Hiroshi Kobayashi Individual 21. Sep 18 25. Sep 18 -13,000 ₹868.99 ₹-11,296,918
11. Sep 18 Sell Munish Talwar Individual 31. Aug 18 31. Aug 18 -6,000 ₹925.45 ₹-5,552,714
31. Aug 18 Sell Shigenori Fukushima Individual 23. Aug 18 23. Aug 18 -3,000 ₹881.78 ₹-2,645,326
16. Aug 18 Buy Gupta Family Trust Company 13. Aug 18 13. Aug 18 1,000 ₹814.49 ₹814,490
01. Aug 18 Sell Debabrata Chakravorty Individual 31. Jul 18 31. Jul 18 -3,500 ₹828.40 ₹-2,898,400
12. Jul 18 Buy Nilesh Gupta Individual 06. Jul 18 06. Jul 18 2,710 ₹925.54 ₹2,508,213
21. Jun 18 Sell Rajvardhan Satam Individual 19. Jun 18 19. Jun 18 -1,400 ₹913.00 ₹-1,278,200
X
Management checks
We assess Lupin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lupin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Lupin Limited (BOM:500257) A Sell At Its Current PE Ratio?

and want to begin learning the link between Lupin Limited (BOM:500257)’s fundamentals and stock market performance. … Lupin Limited (BOM:500257) trades with a trailing P/E of 156.4x, which is higher than the industry average of 25.2x. … Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind.

Simply Wall St -

Company Info

Description

Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. The company offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, anti-TB, and cephalosporin. The company also develops drug delivery systems; and offers biosimilars for various therapies, such as oncology, inflammation, ophthalmology, rheumatoid arthritis, and osteoporosis. In addition, it is involved in the novel drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.

Details
Name: Lupin Limited
500257
Exchange: BSE
Founded: 1968
₹326,877,972,079
452,582,862
Website: http://www.lupin.com
Address: Lupin Limited
Laxmi Towers, B Wing,
3rd floor,
Mumbai,
Maharashtra, 400051,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 500257 Equity Shares Mumbai Stock Exchange IN INR 29. Sep 1999
NSEI LUPIN Equity Shares National Stock Exchange of India IN INR 29. Sep 1999
Number of employees
Current staff
Staff numbers
20,000
Lupin employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 12:36
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/05/28
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.